Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSCEND: Psilocybin for Chronic Neuropathic Pain and Depression
NCT06518720Phase 2Recruiting
- Sponsor
- Center for Addiction and Mental Health
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in chronic neuropathic pain and treatment-resistant depression (TRD), sponsored by Center for Addiction and Mental Health. Primary endpoint: Percentage of participants recruited, enrolled and retained, and number of SAEs/SADRs at 24 months. Started Apr 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
chronic neuropathic paintreatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06518720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518720.